

P#6

RECEIVED
TECH CENTER 1600/2500
03 JAN 16 PM 1:50

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-759-A)

In the Application of:

Fox et al.

Serial No.: 09/95,866 ⁹⁵⁵⁸⁶⁶

Filing Date: September 19, 2001

For: B7-Like Molecules and Uses Thereof

Examiner: To be Assigned

Group Art Unit: 1646

TRANSMITTAL LETTER


Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

- In regard to the above identified application,
1. We are transmitting herewith the attached:
 - a) Third Supplemental Information Disclosure
 - b) PTO Form 1449; and cited references
 - c) Return postcard
 2. With respect to fees:
 - a) No fees are required
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
 3. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited by hand delivery to the Commissioner for Patents, Washington, D.C. 20231 on January 16, 2003.

Respectfully submitted,

Date: 16 January 2003


Donald L. Zuhn.
Registration No. 48,710

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-759-A)

In the Application of:)

Fox et al.)

Serial No.: 09/955,866⁹⁵⁵⁸⁶⁶)

Filing Date: September 19, 2001)

For: B7-Like Molecules and Uses Thereof)

Examiner: To be Assigned)

Group Art Unit: 1646)

TECH CENTER RECEIVED
03 JAN 16 PM 1:50
1500/2600

RECEIVED

JAN 21 2003

INFORMATION DISCLOSURE STATEMENT

TEC.

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:


Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned representative by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Date: January 16, 2003

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff


Donald L. Zuhn
Reg. No. 48,710

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application No.	09/995,866
				Filing Date:	September 19, 2001
				First Named Inventor	Fox et al.
				Group Art Unit	1646
Examiner Name					
Attorney Docket No.	00-759-A				
Sheet	1	of	2		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		EP	1074817	A	Helix Res. Inst.	02-07-01		
		WO	01/34659	A	Human Genome Sciences Inc.	05-17-01		
		WO	00/61612	A	Corixa Corp; Fan Liqun	10-19-00		
		WO	00/55375	A	Alphagene Inc.	09-21-00		
		WO	00/38107	A2	Corixa Corporation	06-22-00		

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Henry et al., "Structure and evolution of the extended B7 family" Immunology Today, Elsevier Publications, Cambridge, GB, vol. 20, no. 6, June 1999, pages 285-288.	
		Database EMBL 'Online' February 22, 2000, Isogai T et al.: Homo Sapiens cDNA FLJ11010 fis, clone PLACE1003145" Database accession no AK001872.	
		Database EMBL 'Online' June 1, 1999, Tseng et al.: "Mus musculus butyrophilin-like protein (btcd) mRNA, complete cds" retrieved from EBI Database accession no. AF142780	
		Database EMBL 'Online' March 9, 2001, Latchman et al.: "Homo sapiens PD-1-ligand 2 protein (PDL2) m RNA, complete cds", Database accession no. AF344424.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known	
		Application No.	09/895,886
		Filing Date:	September 19, 2001
		First Named Inventor	Fox et al.
		Group Art Unit	1846
Sheet 2 of 2	Examiner Name		
		Attorney Docket No.	00-750-A

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Database EMBL, Online "Homo Sapiens butyrophilin precursor B7-DC mRNA, complete cds", Database Accession No. AF329193.1.	
		International Search Report for PCT/US01/29163.	
		Yoshinaga et al., T-cell co-stimulation through B7RP-1 and ICOS", Nature, 402:827-32.	
		Ishida et al., "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death", EMBO J. 11:3887-95.	
		Dong et al., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion", Nat. Med. 5:1385-69.	
		Latchman et al., "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", 2001 Nature Immunology 2:261-68.	
		Nishimura et al., "Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor", Immunity, 11:141-51.	
		Tseng et al., B7-DC, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells", J. Exp. Med. 193:839-45, 2001.	

RECEIVED

JAN 21 2003

TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231